

Personal Information



Arunee Dechaphunkul

Address: Songklanagarind Hospital, Department of Internal Medicine,
Faculty of Medicine, Prince of Songkla University

Country: Thailand

Curriculum Vitae

EDUCATION/TRAINING

INSTITUTION AND LOCATION	DEGREE	YEAR (s)	FIELD OF STUDY
Prince of Songkla University, Thailand	M.D.	2003	Medicine
Prince of Songkla University, Thailand	Diploma	2007	Internal Medicine
Cross Cancer Institute, University of Alberta, Canada	Certificate Clinical Fellowship	2011	Medical Oncology

A. Positions and Honors

Positions and Employment

2003-2004	Medical Internship, Prince of Songkla University, Songkhla , Thailand
2004-2008	Medical Residency, Internal Medicine , Prince of Songkla University, Songkhla , Thailand
2008-2010	Instructor , Division of Medical Oncology, Department of Internal Medicine, Prince of Songkla University, Songkhla, Thailand
2010-2012	Clinical fellowship, Medical Oncology, Cross Cancer Institute, Department of Oncology, University of Alberta , Edmonton , Canada
2012-2013	Instructor, Division of Medical Oncology, Department of Internal Medicine, Prince of Songkla University, Songkhla, Thailand
2013-Present	Assistant Professor, Division of Medical Oncology, Department of Internal Medicine, Prince of Songkla University, Songkhla, Thailand

Other Experience and Professional Memberships

- 2003 Member, Medical Council of Thailand
- 2008 Member, The Royal College of Physicians of Thailand
- 2010 Member, Canadian Association of Medical Oncology
- Member, American Society of Clinical Oncology

B. Bibliography

Publications

1. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. *N Engl J Med* 2018; 378: 113-25.
2. Zhang L, Lu S, Feng J, Dechaphunkul A, Chang J, Wang D, et al. A Randomized Phase 3 Study Evaluating the Efficacy of Single-dose NEPA, a Fixed Antiemetic Combination of Netupitant and Palonosetron, Versus an Aprepitant Regimen for Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC). *Ann Oncol* 2017 Oct 28.
3. [Soulières D](#), [Faivre S](#), [Mesía R](#), [Remenár É](#), [Li SH](#), [Karpenko A](#), [Dechaphunkul A](#), et al. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Oncol* 2017; 18: 323-35.
4. [Dechaphunkul A](#), [Sakdejayont S](#), [Sathitruangsak C](#), [Sunpaweravong P](#). Clinical Characteristics and Treatment Outcomes of Patients with Primary Mediastinal Germ Cell Tumors: 10-Years' Experience at a Single Institution with a Bleomycin-Containing Regimen. [Oncol Res Treat](#) 2016; 39: 688-94.
5. [Goh G](#), [Schmid R](#), [Guiver K](#), [Arpornwirat W](#), [Chitapanarux I](#), [Ganju V](#), et al. Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. [PLoS Med](#) 2016;13 (12):e1002136.
6. Leighl NB, Rizvi NA, de Lima LG Jr, Arpornwirat W, Rudin CM, Chiappori AA, et al. Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. [Clin Lung Cancer](#) 2016: S1525-7304(16)30187-5.
7. [Thatcher N](#), [Hirsch FR](#), [Luft AV](#), [Szczesna A](#), [Ciuleanu TE](#), [Dediu M](#), et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. [Lancet Oncol](#) 2015; 16: 763-74.
8. Sathitruangsak C, and Dechaphunkul A. Neurological Complications of Chemotherapy and Radiotherapy in Cancer Patients. *Songkla Med J* 2014; 32: 259-70.

9. Tanapathomsinchai N, Dechaphunkul A, and Sathitruangsak C. Cancer-associated Thromboembolism. *Songkla Med J* 2014; 32: 185-93.
10. Pervez N, El-Gehani F, Joseph K, Dechaphunkul A, Kamal M, et al. Genitourinary small-cell carcinoma: a single-institution experience. *Current Oncology* 2013; 20: 258-64.
11. Dechaphunkul A, Mulder K, El-Gehani F, Ghosh S, Deschenes J, Spratlin J. Clinicopathologic characteristics and survival outcomes of patients with advanced esophageal, gastro-esophageal junction, and gastric adenocarcinoma : a single institution experience. *Current Oncology* 2012; 19: 302-7.
12. Dechaphunkul A, Phukaoloun M, Kanjanapradit K, Graham K, Ghosh S, Santos C, Mackey JR. Prognostic significance of Tissue Inhibitor of Metalloproteinase-1 in breast cancer. *Int J Breast Cancer* 2012; 2012: 290854.
13. Dechaphunkul A, Bigras G, Sawyer M. Response to 5-fluorouracil-based chemotherapy in a patient with metastatic colonic-type adenocarcinoma arising in a primary mediastinal teratoma. *Case Rep Oncol Med* 2012; 2012: 729278.
14. Dechaphunkul A, Kayasut K, Oearsakul T, Sunpaweravong P. A common presentation in an uncommon disease: case report of a patient with primary diffuse leptomeningeal melanocytosis. *J Clin Oncol* 2011; 29: e816-e818.
15. Dechaphunkul A, Chacranon M, Chaiwiriyawong S, Sunpaweravong P. Antihormonal Therapy in Breast Cancer. *Songkla Med J* 2011; 29: 127-142.
16. Saeai N, Dechaphunkul A, Sunpaweravong P. Renal and liver impairment in patients receiving cytotoxic chemotherapy. *Songkla Med J* 2010; 28: 49-59.
17. Dechaphunkul A, Kanngurn S, Dechsukhum C, Sunpaweravong P. The Significance of Galectin-3 Immunohistochemistry, Clinical Characteristics and Liver Imaging in Differentiating Intrahepatic Cholangiocarcinoma from Adenocarcinoma Liver Metastasis. *J Med Assoc Thai* 2010; 93: 523-8.

Abstracts

1. Sakdejyont S, Sathitruangsak C, Sunpaweravong P, and Dechaphunkul A. Clinical Characteristics and Treatment Outcomes of Patients with Primary Mediastinal Germ Cell Tumors: 10-Year Experiences in a Single Institution with Bleomycin-Containing Regimen. (Poster Presentation: Genitourinary Cancers Symposium 2014 in San Francisco, United States).
 2. El-Gehani F, Breckenridge Z, Dechaphunkul A, et al. Efficacy and safety of chemotherapy in elderly patients with metastatic non-small cell lung cancer: Single institution experience. (Poster Presentation: the 3rd European Lung Cancer Conference (ELCC) in Geneva, Switzerland)
1. El-Gehani F, Dechaphunkul A, Kamal M, et al. Small cell carcinoma of the genitourinary tract: A 10-year single institution experience. (Poster Presentation: GU ASCO 2012 in San Francisco, USA)
 2. Dechaphunkul A, Phukaoloun M, Kanjanapradit K, et al. Prognostic significance of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in breast cancer. (Poster Presentation: San Antonio Breast Cancer Symposium 2011 in San Antonio, Texas USA)

3. El-Gehani F, Dechaphunkul A, Kamal M, et al. Small cell carcinoma of urinary bladder: A 10-year single institution experience. (Poster Presentation: 3rd European Multidisciplinary Meeting on Urological Cancer 2011 in Barcelona, Spain)

C. Experience in clinical research

1. Phase IIb/III Randomized, Double-Blind Trial of BIBW 2992 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Non-Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (Lux_Lung)
2. A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer(CLEOPATRA)
3. A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients With HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab With Chemotherapy Plus Trastuzumab Plus Bevacizumab(BETH)
4. A Randomised, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ErbB2 Positive Primary Breast Cancer(ALTTO)
5. A Randomized, Open Label Study to Compare the Complete Pathological Response Rate Achieved With Herceptin Plus Docetaxel, Versus Herceptin Plus Docetaxel Plus Pertuzumab, Versus Herceptin Plus Pertuzumab, Versus Pertuzumab and Docetaxel in Patients With Locally Advanced, Inflammatory or Early Stage HER2 positive Breast Cancer (Neosphere)
6. A Phase III, Multi-Center, Placebo-Controlled Trial of Sorafenib (BAY 43-9006) in Patients With Relapsed or Refractory Advanced Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC) After 2 or 3 Previous Treatment Regimens(MISSION)
7. A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3+AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer(MAGEA-3)
8. A Randomized, Open Label, Multi-Center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
9. Randomized Phase III Trial Comparing Nilotinib 800mg to Imatinib 800 mg for the Treatment of Patients With Advanced and/or Metastatic Gastrointestinal Stromal Tumors Refractory to Imatinib 400 mg
10. A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney
11. An International, Multi-Centre, Open-label, 2 arm, Phase III trial of Adjuvant Bevacizumab in “Triple negative” Breast Cancer
12. Phase II study of histology-guided chemotherapy in stage IIIb/IV non-small cell lung cancer with pemetrexed plus platinum for non-squamous and taxane plus platinum for squamous and non-squamous carcinomas

- 13.A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN, AZD2171) in Combination with 5 fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination with FOLFOX in Patients with Previously Untreated Metastatic Colorectal Cancer
- 14.A phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with docetaxel in second-line treatment of patients with locally advanced or metastatic (stage IIIb/IV) non-small cell lung cancer (NSCLC)”
- 15.Assessment of Urine N-telopeptide (uNTx) in patients with local advanced or metastatic non-small cell lung cancer (NSCLC)
- 16.A Randomized Phase 3, doubled blind, placebo-controlled multicenter trial of daily everolimus in combination with trastuzumab and vinorelbine, in pretreated women with HER2/neu over expressing locally advanced or metastatic breast cancer
- 17.A Randomized Phase 3 Study Comparing First-Line Pemetrexed plus Cisplatin (Followed by Gefitinib as Maintenance) with Gefitinib Monotherapy in East Asian (Never Smoker or Light Ex-Smoker) Patients with Locally Advanced or Meatastatic Nonsquamous Non-Small Cell Lung Cancer
- 18.A Phase III study of ErbB2 positive advanced or metastatic gastric or esophageal or gastroesophageal junction adenocarcinoma treated with capecitabine plus Oxaliplatin with or without Lapatinib.
- 19.A Randomized Phase 3, doubled blind, placebo-controlled multicenter trial of daily everolimus in combination with trastuzumab and vinorelbine, in pretreated women with HER2/neu over expressing locally advanced or metastatic breast cancer
- 20.A Randomized, Multicenter, Open-Label, Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus IMC-11F8 Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Squamous Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC)
- 21.A Randomized, Open label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.
- 22.A randomized, 3 arm, multicentre, phase III study to evaluate the efficacy and the safety of T-DM1 combined with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab), versus the combination of trastuzumab plus taxane, as first line treatment in HER2-positive progressive or recurrent locally advanced or metastatic breast cancer (MBC)
- 23.A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib
- 24.A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination with Anastrozole, Compared to Anastrozole alone, in Post-menopausal Women with Hormone Receptor-positive, Endocrine Therapy-naive, Locally-advanced or Metastatic Breast Cancer
- 25.A randomized, phase III, open label, multi-center, two-arm study to compare the efficacy of Tasigna[®] versus dacarbazine (DTIC) in the treatment of patients with metastatic and/or inoperable melanoma harboring a c-Kit mutation

26. Efficacy and Safety of Long-Term (6 Months) Innohep[®] Treatment Versus Anticoagulation with a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients
27. A Randomized, Double-Blind, Placebo-controlled Phase 2 Study of erlotinib (Tarceva[®]) in combination with OSI 906 or placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor (EGFR) Gene
28. A prospective, randomized, multicenter, open-label, Phase III Study of active specific immunotherapy with racotumomab plus best supportive treatment versus best supportive treatment in patients with advanced non-small cell lung cancer. (RACO)
29. A Multicenter, Double-blind, Randomized, Parallel-Group, Phase III Study to Compare the Efficacy and Safety of Hercules Versus Herceptin[®] in patients with HER2+ Metastatic Breast Cancer.
30. Randomized, Multicenter, Double-Blind, Phase III Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects with Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC)
31. A phase II, double-blind, placebo-controlled, randomized study of GDC-0941 or GDC-0980 with Fulvestrant versus Fulvestrant in advanced or metastatic breast cancer in patients resistant to Aromatase inhibitor therapy. (FERGI)
32. An open label, phase II trial of afatinib with or without vinorelbine for the treatment of HER2-overexpressing Inflammatory Breast Cancer .
33. Randomized, Multicenter, Double-Blind, Phase III Trial Comparing the Efficacy of Ipilimumab Plus Etoposide/Platinum versus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)
34. A Phase III, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC)
35. A Phase III, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy (MEC)
36. An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
37. A randomized, phase III, multicenter, double-blind, placebo-controlled study evaluating the efficacy and safety of Onartuzumab (MetMab) in combination with 5 Fluorouracil, Folinic acid, and Oxaliplatin (mFOLFOX6) in patients with metastatic HER2 negative, MET-positive gastroesophageal cancer (YO28322)
38. A Double-blind, placebo-controlled, randomized, multicenter phase III study evaluating the efficacy and safety of Pertuzumab in combination with Trastuzumab and chemotherapy in patients with HER2-positive metastatic gastroesophageal junction and gastric cancer

39. A phase II study of BKM120; a pan-PI3K inhibitor in patients with esophageal squamous cell carcinoma after failure of first-line chemotherapy
40. Phase I, Dose-Escalation Study of Soluble Beta-Glucan (SBG) in Patients
With Advanced Solid Tumors
41. Phase II multicenter randomized, double blind, placebo controlled study
assessing the efficacy of buparlisib (BKM120) plus paclitaxel vs. placebo plus paclitaxel in patients with platinum pre-treated recurrent or metastatic head and neck squamous cell carcinoma.
42. A randomized, double-blind, double-dummy, parallel group, international multicenter study assessing the efficacy and safety of a netupitant-palonosetron Fixed Dose Combination (FDC) compared to an extemporaneous combination of granisetron and aprepitant on the prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with cancer
43. An Open-label, Multi-Center Study to Investigate the Objective Response Rate of Dabrafenib in Combination with Trametinib in Subjects with BRAF V600 E/K Mutation - Positive Acral Lentiginous Melanoma.
44. A Phase II, multicenter, single-arm study of oral LDK378 in crizotinib naïve adult patients with ALK-activated non-small cell lung cancer.
45. A randomized, open label phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and / or metastatic head and neck squamous cell carcinoma who have progressed after platinum-based therapy.
46. A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients with metastatic colorectal cancer
47. A Randomized, Double-blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination with Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy. (The JANUS 1 Study)
48. A Phase III, open-label, multicentre, randomised trial to establish safety and efficacy of an EGF cancer vaccine in inoperable, stage IV biomarker positive, wild-type EGFR non-small cell lung cancer (NSCLC) patients eligible to receive standard treatment and supportive care.
49. A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer)
50. A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-III A Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)
51. A phase II, open-label, randomized controlled study of PDR001 in patients with moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progressed on standard treatment (CPDR001X2201)

52. A Phase III, Multicenter, Randomized, Placebo-controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with NAB-Paclitaxel compared with Placebo with NAB-Paclitaxel for Patients with Previously Untreated Metastatic Triple-negative Breast Cancer (WO29522)
53. A Phase III, double-blind, placebo-controlled, randomized study of Taselisib plus Fulvestrant versus Placebo plus Fulvestrant in postmenopausal women with estrogen receptor-positive and HER2-negative locally advanced or metastatic breast cancer who have disease recurrence or progression during or after Aromatase Inhibitor therapy (GO29088)
54. A Phase 1b/2 Open-Label Study Of Imu-131 Her2/Neu Peptide Vaccine Plus Cisplatin And Either 5-Fluorouracil or Capecitabine Chemotherapy In Patients With Her2/Neu Overexpressing Metastatic or Advanced Adenocarcinoma of The Stomach or Gastroesophageal Junction (IMU-131)
55. A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients (KESTREL)
56. A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination with Bevacizumab versus Sunitinib in Patients with Untreated Advanced Renal Cell Carcinoma (RCC)
57. An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations (SOLAR study)
58. A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)
59. A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)
60. A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF/Thymidine Kinase- Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)
61. Clinical and Molecular Alteration Study of Head and Neck Cancer Study: A Multicenter Collaboration
62. Evaluation of cisplatin-induced nephrotoxicity using short course hydration in patients with head and neck cancer received concurrent chemoradiation with high-dose cisplatin: A retrospective analysis in a single institution
63. Efficacy and safety of Afatinib in advanced non-small cell lung cancer patients with prior exposure to first generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs)
64. Open label multicenter Phase I/II study of the safety and efficacy of PDR001 administered to patients with advanced malignancies (Melanoma)